Loading...

ContextVision

OB:COV
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
COV
OB
NOK553M
Market Cap
  1. Home
  2. NO
  3. Healthcare
Company description

ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers worldwide. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
COV Share Price and Events
7 Day Returns
2.9%
OB:COV
0.3%
Europe Healthcare Services
-1.3%
NO Market
1 Year Returns
35.4%
OB:COV
12.3%
Europe Healthcare Services
-4.3%
NO Market
COV Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ContextVision (COV) 2.9% -6.5% 16.8% 35.4% 150.9% 358.3%
Europe Healthcare Services 0.3% 2% 9.7% 12.3% 31.9% 105.7%
NO Market -1.3% -4.9% -3.7% -4.3% 26.9% 14.7%
1 Year Return vs Industry and Market
  • COV outperformed the Healthcare Services industry which returned 12.3% over the past year.
  • COV outperformed the Market in Norway which returned -4.3% over the past year.
Price Volatility
COV
Industry
5yr Volatility vs Market

COV Value

 Is ContextVision undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ContextVision to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ContextVision.

OB:COV Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.6%
Perpetual Growth Rate 10-Year NO Government Bond Rate 1.8%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OB:COV
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year NO Govt Bond Rate 1.8%
Equity Risk Premium S&P Global 6%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 1.23
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.226 (1 + (1- 22%) (0%))
1.152
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.15
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.76% + (1.152 * 5.96%)
8.62%

Discounted Cash Flow Calculation for OB:COV using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ContextVision is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

OB:COV DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SEK, Millions) Source Present Value
Discounted (@ 8.62%)
2019 -5.10 Analyst x1 -4.69
2020 -2.40 Analyst x1 -2.03
2021 38.00 Analyst x1 29.65
2022 65.45 Est @ 72.25% 47.02
2023 98.90 Est @ 51.1% 65.40
2024 134.80 Est @ 36.3% 82.07
2025 169.77 Est @ 25.94% 95.15
2026 201.49 Est @ 18.68% 103.96
2027 228.91 Est @ 13.61% 108.73
2028 251.92 Est @ 10.05% 110.16
Present value of next 10 years cash flows SEK635.40
OB:COV DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= SEK251.92 × (1 + 1.76%) ÷ (8.62% – 1.76%)
SEK3,734.96
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SEK3,734.96 ÷ (1 + 8.62%)10
SEK1,633.21
OB:COV Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SEK635.40 + SEK1,633.21
SEK2,268.61
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK2,268.61 / 7.74
SEK293.22
OB:COV Discount to Share Price
Calculation Result
Exchange Rate SEK/NOK
(Reporting currency to currency of OB:COV)
0.911
Value per Share
(NOK)
= Value per Share in SEK x Exchange Rate (SEK/NOK)
= SEK293.22 x 0.911
NOK267.14
Value per share (NOK) From above. NOK267.14
Current discount Discount to share price of NOK71.50
= -1 x (NOK71.50 - NOK267.14) / NOK267.14
73.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ContextVision is available for.
Intrinsic value
>50%
Share price is NOK71.5 vs Future cash flow value of NOK267.14
Current Discount Checks
For ContextVision to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ContextVision's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ContextVision's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ContextVision's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ContextVision's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OB:COV PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK-0.15
OB:COV Share Price ** OB (2019-05-24) in NOK NOK71.5
OB:COV Share Price converted to SEK reporting currency Exchange rate (NOK/ SEK) 1.098 SEK78.48
Europe Healthcare Services Industry PE Ratio Median Figure of 20 Publicly-Listed Healthcare Services Companies 28.95x
Norway Market PE Ratio Median Figure of 133 Publicly-Listed Companies 13.7x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ContextVision.

OB:COV PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:COV Share Price ÷ EPS (both in SEK)

= 78.48 ÷ -0.15

-515.01x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ContextVision is loss making, we can't compare its value to the Europe Healthcare Services industry average.
  • ContextVision is loss making, we can't compare the value of its earnings to the Norway market.
Price based on expected Growth
Does ContextVision's expected growth come at a high price?
Raw Data
OB:COV PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -515.01x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
68%per year
Europe Healthcare Services Industry PEG Ratio Median Figure of 12 Publicly-Listed Healthcare Services Companies 2.26x
Norway Market PEG Ratio Median Figure of 102 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ContextVision, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ContextVision's assets?
Raw Data
OB:COV PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK7.57
OB:COV Share Price * OB (2019-05-24) in NOK NOK71.5
OB:COV Share Price converted to SEK reporting currency Exchange rate (NOK/ SEK) 1.098 SEK78.48
Europe Healthcare Services Industry PB Ratio Median Figure of 40 Publicly-Listed Healthcare Services Companies 2.46x
Norway Market PB Ratio Median Figure of 212 Publicly-Listed Companies 1.14x
OB:COV PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:COV Share Price ÷ Book Value per Share (both in SEK)

= 78.48 ÷ 7.57

10.37x

* Primary Listing of ContextVision.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ContextVision is overvalued based on assets compared to the Europe Healthcare Services industry average.
X
Value checks
We assess ContextVision's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. ContextVision has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

COV Future Performance

 How is ContextVision expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
68%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ContextVision expected to grow at an attractive rate?
  • ContextVision's earnings growth is expected to exceed the low risk savings rate of 1.8%.
Growth vs Market Checks
  • ContextVision's earnings growth is expected to exceed the Norway market average.
  • ContextVision's revenue growth is expected to exceed the Norway market average.
Annual Growth Rates Comparison
Raw Data
OB:COV Future Growth Rates Data Sources
Data Point Source Value (per year)
OB:COV Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 68%
OB:COV Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 19.3%
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 7.1%
Norway Market Earnings Growth Rate Market Cap Weighted Average 13.9%
Norway Market Revenue Growth Rate Market Cap Weighted Average 3.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OB:COV Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OB:COV Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 227 1
2022-12-31 209 1
2021-12-31 149 73 34 2
2020-12-31 116 32 16 2
2019-12-31 95 26 13 2
OB:COV Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 91 5 -1
2018-09-30 85 5 -2
2018-06-30 82 5 -3
2018-03-31 82 4 -2
2017-12-31 81 2 -2
2017-09-30 83 5 -1
2017-06-30 85 1 1
2017-03-31 81 4 0
2016-12-31 82 10 4
2016-09-30 76 6 3
2016-06-30 73 10 4
2016-03-31 72 12 5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ContextVision's earnings are expected to grow significantly at over 20% yearly.
  • ContextVision's revenue is expected to grow by 19.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OB:COV Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from ContextVision Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:COV Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 4.37 7.41 1.32 2.00
2020-12-31 2.09 3.24 0.94 2.00
2019-12-31 1.64 2.23 1.05 2.00
OB:COV Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 -0.15
2018-09-30 -0.30
2018-06-30 -0.45
2018-03-31 -0.28
2017-12-31 -0.22
2017-09-30 -0.17
2017-06-30 0.13
2017-03-31 0.06
2016-12-31 0.55
2016-09-30 0.36
2016-06-30 0.48
2016-03-31 0.64

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • ContextVision is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess ContextVision's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ContextVision has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

COV Past Performance

  How has ContextVision performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ContextVision's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ContextVision does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ContextVision's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ContextVision's 1-year growth to the Europe Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
ContextVision's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ContextVision Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OB:COV Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 90.90 -1.18 33.15
2018-09-30 85.44 -2.29 31.92
2018-06-30 81.59 -3.47 29.75
2018-03-31 82.46 -2.18 29.37
2017-12-31 80.51 -1.71 27.94
2017-09-30 82.90 -1.29 28.35
2017-06-30 85.20 1.04 28.24
2017-03-31 80.76 0.49 25.53
2016-12-31 81.92 4.25 23.37
2016-09-30 75.81 2.82 20.83
2016-06-30 72.52 3.71 18.84
2016-03-31 72.28 4.97 18.06
2015-12-31 72.24 5.34 18.39
2015-09-30 69.72 5.40 16.88
2015-06-30 67.46 3.99 17.62
2015-03-31 65.21 5.39 18.17
2014-12-31 64.40 5.42 18.86
2014-09-30 63.63 7.52 18.63
2014-06-30 64.72 9.07 18.03
2014-03-31 62.91 5.45 19.30
2013-12-31 61.28 4.88 18.57
2013-09-30 66.32 3.61 19.81
2013-06-30 65.79 2.56 20.13
2013-03-31 67.84 1.15 22.99
2012-12-31 67.12 0.62 23.19
2012-09-30 63.77 0.01 22.47
2012-06-30 62.14 -0.02 22.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ContextVision has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ContextVision has efficiently used its assets last year compared to the Europe Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ContextVision improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ContextVision's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ContextVision has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

COV Health

 How is ContextVision's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ContextVision's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ContextVision is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ContextVision's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ContextVision's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • ContextVision has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ContextVision Company Filings, last reported 4 months ago.

OB:COV Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 58.56 0.00 37.95
2018-09-30 55.55 0.00 40.80
2018-06-30 54.45 0.00 37.04
2018-03-31 55.58 0.00 40.73
2017-12-31 59.35 0.00 40.33
2017-09-30 57.79 0.00 42.82
2017-06-30 58.77 0.00 37.81
2017-03-31 58.80 0.00 40.95
2016-12-31 61.43 0.00 42.91
2016-09-30 59.05 0.00 38.96
2016-06-30 57.52 0.00 38.58
2016-03-31 58.17 0.00 38.03
2015-12-31 57.04 0.00 35.64
2015-09-30 56.05 0.00 35.66
2015-06-30 53.65 0.00 32.09
2015-03-31 52.64 0.00 30.26
2014-12-31 50.75 0.00 31.13
2014-09-30 50.49 0.00 33.54
2014-06-30 49.19 0.00 29.18
2014-03-31 47.06 0.00 31.76
2013-12-31 45.53 0.00 29.16
2013-09-30 42.79 0.00 26.85
2013-06-30 40.39 0.00 23.59
2013-03-31 42.21 0.00 27.21
2012-12-31 41.05 0.00 24.72
2012-09-30 39.62 0.00 22.46
2012-06-30 38.22 0.00 17.87
  • ContextVision has no debt.
  • ContextVision has not taken on any debt in the past 5 years.
  • ContextVision has no debt, it does not need to be covered by operating cash flow.
  • ContextVision has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess ContextVision's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ContextVision has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

COV Dividends

 What is ContextVision's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ContextVision dividends. Estimated to be 0% next year.
If you bought NOK2,000 of ContextVision shares you are expected to receive NOK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ContextVision's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ContextVision's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OB:COV Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.5%
Norway Market Average Dividend Yield Market Cap Weighted Average of 109 Stocks 4.5%
Norway Minimum Threshold Dividend Yield 10th Percentile 1.8%
Norway Bottom 25% Dividend Yield 25th Percentile 2.5%
Norway Top 25% Dividend Yield 75th Percentile 6.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OB:COV Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
OB:COV Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2009-10-12 0.000 0.000
2009-08-20 0.000 0.000

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ContextVision has not reported any payouts.
  • Unable to verify if ContextVision's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ContextVision's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ContextVision has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of ContextVision's dividends in 3 years as they are not expected to pay a notable one for Norway.
X
Income/ dividend checks
We assess ContextVision's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ContextVision afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ContextVision has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

COV Management

 What is the CEO of ContextVision's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Fredrik Palm
TENURE AS CEO 0.1 years
CEO Bio

Mr. Fredrik Palm has been the Chief Executive Officer of ContextVision AB (publ) since April 1, 2019. He was Vice President of Sales at ContextVision AB (publ) since January 2012 until April 1, 2019. He served as a Vice President of OEM Business at ContextVision AB. Mr. Palm has over 20 years of experience from companies within life science, where he has mainly worked from the marketing and sales side in a global perspective. Since 2012, he has led the marketing and sales activities at ContexVision, where revenue during the period has increased from SEK 60 million to more than SEK 90 million last year. After many years at Waters Corporation, he moved on to several sales and marketing positions at medical device companies, focusing on international expansion. His experience covers international sales, marketing and business development as well as concepts for value based communication. He has complemented his engineer background with studies in business management and strategic marketing.

CEO Compensation
  • Insufficient data for Fredrik to compare compensation growth.
  • Insufficient data for Fredrik to establish whether their remuneration is reasonable compared to companies of similar size in Norway.
Management Team Tenure

Average tenure of the ContextVision management team in years:

4.1
Average Tenure
  • The tenure for the ContextVision management team is about average.
Management Team

Sven Günther-Hanssen

TITLE
Co-Founder & Director
AGE
64

Martin Hedlund

TITLE
Co-Founder
COMPENSATION
SEK2M
AGE
66
TENURE
20.3 yrs

Fredrik Palm

TITLE
Chief Executive Officer
TENURE
0.1 yrs

Ann-Charlotte Linderoth

TITLE
Chief Financial Officer
TENURE
4.1 yrs
Board of Directors Tenure

Average tenure and age of the ContextVision board of directors in years:

8.3
Average Tenure
59.5
Average Age
  • The tenure for the ContextVision board of directors is about average.
Board of Directors

Erik Danielsen

TITLE
Chairman of the Board
COMPENSATION
SEK300K
AGE
55
TENURE
9.3 yrs

Sven Günther-Hanssen

TITLE
Co-Founder & Director
AGE
64

Martin Hedlund

TITLE
Co-Founder
COMPENSATION
SEK2M
AGE
66
TENURE
22.3 yrs

Karin Bernadotte

TITLE
Director
COMPENSATION
SEK200K
AGE
55
TENURE
8.3 yrs

Fredrik Pontén

TITLE
Digital Pathology Advisory Board Member
TENURE
1.5 yrs

Junya Fukuoka

TITLE
Digital Pathology Advisory Board Member
TENURE
1.5 yrs

Anil Parwani

TITLE
Digital Pathology Advisory Board Member

Jeroen van der Laak

TITLE
Digital Pathology Advisory Board Member

Dan Ciresan

TITLE
Digital Pathology Advisory Board Member

Henning Müller

TITLE
Digital Pathology Advisory Board Member
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NOK) Value (NOK)
09. Dec 18 Sell Anita Tollstadius Individual 06. Dec 18 06. Dec 18 -225 NOK55.02 NOK-12,380
X
Management checks
We assess ContextVision's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ContextVision has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

COV News

Simply Wall St News

How Much Of ContextVision AB (publ) (OB:COV) Do Insiders Own?

As Charlie Munger said 'Show me the incentive and I will show you the outcome.' ContextVision is a smaller company with a market capitalization of øre534m, so it may still be flying under the radar of many institutional investors. … Check out our latest analysis for ContextVision OB:COV Ownership Summary, May 15th 2019 What Does The Institutional Ownership Tell Us About ContextVision? … Private Company Ownership It seems that Private Companies own 43%, of the COV stock.

Simply Wall St -

Does ContextVision AB (publ)'s (OB:COV) CEO Salary Compare Well With Others?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Anita Tollstadius's Compensation Compare With Similar Sized Companies. … We examined a group of similar sized companies, with market capitalizations of below kr1.9b

Simply Wall St -

What Kind Of Shareholder Owns Most ContextVision AB (publ) (OB:COV) Stock?

A look at the shareholders of ContextVision AB (publ) (OB:COV) can tell us which group is most powerful. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … ContextVision is not a large company by global standards.

Simply Wall St -

Is ContextVision AB (publ) (OB:COV) A Financially Sound Company?

The direct benefit for ContextVision AB (publ) (OB:COV), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is financial flexibility worth the lower cost of capital … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital.

Simply Wall St -

Should You Worry About ContextVision AB (publ)'s (OB:COV) CEO Pay Cheque?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Anita Tollstadius's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that ContextVision AB (publ) has a market cap of øre450m, and is paying total annual CEO compensation of kr2.3m.

Simply Wall St -

Is There An Opportunity With ContextVision AB (publ)'s (OB:COV) 40.83% Undervaluation?

How far off is ContextVision AB (publ) (OB:COV) from its intrinsic value? … by taking the expected future cash flows and discounting them to their present value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

Why I Like ContextVision AB (publ) (OB:COV)

As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … financial health as well as

Simply Wall St -

Should You Be Concerned About ContextVision AB (publ)'s (OB:COV) Investors?

Today, I will be analyzing ContextVision AB (publ)’s (OB:COV) recent ownership structure, an important but not-so-popular subject among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Differences in ownership structure of companies can have a profound effect on how management's incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices.

Simply Wall St -

Looking At ContextVision AB (publ) (OB:COV) From All Angles

ContextVision AB (publ) (OB:COV) is a company with exceptional fundamental characteristics. … Upon building up an investment case for a stock, we should look at various aspects. … Below is a brief commentary on these key aspects.

Simply Wall St -

Who Are The Top Investors In ContextVision AB (publ) (OB:COV)?

Check out our latest analysis for ContextVision OB:COV Ownership_summary May 16th 18 Institutional Ownership In COV's case, institutional ownership stands at 15.79%, significant enough to cause considerable price moves in the case of large institutional transactions, especially when there is a low level of public shares available on the market to trade. … With this size of ownership in COV, this ownership class can affect the company's business strategy. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

COV Company Info

Description

ContextVision AB (publ), a medical technology software company, provides image analysis and artificial intelligence software solutions to original equipment manufacturers worldwide. It operates through two segments, Medical Imaging and Digital Pathology. The company offers image enhancement software for 2D/3D/4D ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Its products include US PLUSView, an image enhancement software product for women’s health, general imaging, cardiovascular, and point of care applications; VolarView, an image enhancement software for the handheld ultrasound market segment; GOPiCE, a technology for volumetric image enhancement in real-time; and REALiCE, a volume enhancement and rendering solution for visualization. The company also provides Altumira/Altumira Plus, a solution for various digital radiography systems; GOPView XR2Plus for x-ray systems for human and veterinary examinations; Orthopedic Package for orthopedic imaging; and GOPView iRVUltra, a software for noise suppression, edge, and contrast enhancement in real time. In addition, it offers GOPView MRI2Plus, an image enhancement solution for MRI; GOPView Mammo3, an image enhancement software for screening and diagnostic mammography; and INIFY Prostate, an AI-based software that outlines and quantifies suspected cancerous areas in a series of prostate biopsies. ContextVision AB (publ) was founded in 1983 and is headquartered in Stockholm, Sweden.

Details
Name: ContextVision AB (publ)
COV
Exchange: OB
Founded: 1983
NOK553,177,625
7,736,750
Website: http://www.contextvision.com
Address: ContextVision AB (publ)
Klara Norra Kyrkogata 31,
Stockholm,
Stockholm County, 111 22,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB COV Common Shares Oslo Bors NO NOK 18. Mar 1997
BATS-CHIXE COVO Common Shares BATS 'Chi-X Europe' GB NOK 18. Mar 1997
Number of employees
Current staff
Staff numbers
42
ContextVision employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/25 20:43
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/04/30
Last earnings filing: 2019/04/04
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.